about akston
process
pipeline
news
careers
contact
NEWS
12 April 2022
Akston Biosciences CEO to Present at the World Vaccine Congress
Akston Biosciences CEO to Present at the World Vaccine Congress
7 April 2022
COVID-19 vaccine: Akston Biosciences doses first volunteers in Phase II/III trial
COVID-19 vaccine: Akston Biosciences doses first volunteers in Phase II/III trial
7 April 2022
Akston Biosciences Doses First Volunteers in Phase II/III Clinical Trial of Low Cost, Shelf Stable COVID-19 Vaccine
Akston Biosciences Doses First Volunteers in Phase II/III Clinical Trial of Low Cost, Shelf Stable COVID-19 Vaccine
31 March 2022
Akston Biosciences Receives Regulatory Approval for Phase II Clinical Trial for Shelf-Stable COVID-19 Vaccine Booster
Akston Biosciences Receives Regulatory Approval for Phase II Clinical Trial for Shelf-Stable COVID-19 Vaccine Booster
18 March 2022
Will the Second Wave of COVID-19 Vaccines Have the Improved Properties Needed to End the Pandemic?
Will the Second Wave of COVID-19 Vaccines Have the Improved Properties Needed to End the Pandemic?
17 March 2022
Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries
Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries
17 March 2022
Stelis Licenses Akston’s AKS-452 Thermostable Protein Subunit COVID Vax
Stelis Licenses Akston’s AKS-452 Thermostable Protein Subunit COVID Vax
17 March 2022
2nd Generation COVID-19 Vaccine Available in 130+ Countries
2nd Generation COVID-19 Vaccine Available in 130+ Countries
17 March 2022
Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries
Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries
23 February 2022
Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
1
4
5
6
11
